• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2016 News Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
Jan 13, 2016MiMedx Completes Acquisition Of Stability Biologics
MARIETTA, Ga., Jan. 13, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the completion of the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, faci... 
Printer Friendly Version
Jan 10, 2016MiMedx Exceeds Fourth Quarter And Full Year 2015 Revenue Consensus
$187.3 MILLION FULL YEAR 2015 REVENUE IS 58% INCREASE OVER 2014 AND $51.8 MILLION Q4 2015 REVENUE IS 31% INCREASE OVER Q4 2014 MARIETTA, Ga., Jan. 10, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its... 
Printer Friendly Version
Jan 10, 2016MiMedx Signs Definitive Agreement To Acquire Stability Biologics
COMPANY ISSUES REVISED GUIDANCE AND EXPECTS 2016 REVENUE IN THE RANGE OF $260 TO $270 MILLION AND ADJUSTED EPS* IN THE RANGE OF $0.33 TO $0.37 MARIETTA, Ga., Jan. 10, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, ann... 
Printer Friendly Version
Jan 06, 2016MiMedx Receives Certificate From FDA Allowing The Export Of MiMedx Allografts
COMPANY'S SHEET HCT/P PRODUCTS CERTIFIED TO BE MARKETED IN, AND LEGALLY EXPORTED FROM, THE U.S. MARIETTA, Ga., Jan. 6, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced that it has recently posted an updated "C... 
Printer Friendly Version

Products

CONTACT US

888.543.1917